ATE124865T1 - Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. - Google Patents

Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.

Info

Publication number
ATE124865T1
ATE124865T1 AT87311079T AT87311079T ATE124865T1 AT E124865 T1 ATE124865 T1 AT E124865T1 AT 87311079 T AT87311079 T AT 87311079T AT 87311079 T AT87311079 T AT 87311079T AT E124865 T1 ATE124865 T1 AT E124865T1
Authority
AT
Austria
Prior art keywords
consciousness
heterocyclic compounds
treat disorders
disorders
attentional
Prior art date
Application number
AT87311079T
Other languages
English (en)
Inventor
Michael Brian Tyers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE124865T1 publication Critical patent/ATE124865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87311079T 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen. ATE124865T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (1)

Publication Number Publication Date
ATE124865T1 true ATE124865T1 (de) 1995-07-15

Family

ID=27449858

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln
AT87311079T ATE124865T1 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93201171T ATE152623T1 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln

Country Status (7)

Country Link
US (1) US4985437A (de)
EP (3) EP0559297B1 (de)
JP (1) JP2608079B2 (de)
AT (2) ATE152623T1 (de)
DE (2) DE3752062T2 (de)
ES (1) ES2074981T3 (de)
GR (1) GR3017369T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
AU5650890A (en) * 1989-05-24 1990-12-18 Nippon Shinyaku Co. Ltd. Indole derivatives and medicine
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
DE69111816T4 (de) * 1990-08-31 1996-08-01 Nippon Shinyaku Co Ltd Indolederivate und ihre verwendung als serotonin-antagoniste.
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
CN1118990A (zh) * 1993-03-08 1996-03-20 藤泽药品工业株式会社 治疗或预防脑血管疾病药物
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
BR0212477A (pt) * 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
EA007429B1 (ru) 2001-10-02 2006-10-27 Фармация Энд Апджон Компани Азабициклические замещённые конденсированные гетероарильные соединения
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
EP1476448A2 (de) * 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Azabicyclische verbindungen zur behandlung von erkrankungen
BR0307735A (pt) * 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
US7001900B2 (en) * 2002-02-20 2006-02-21 Pfizer Inc. Azabicyclic compounds for the treatment of disease
CA2503786A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0385517B1 (de) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Arzneimittel zur Behandlung von Erbrechen
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
EP0342558B1 (de) * 1988-05-16 1994-02-02 G.D. Searle & Co. 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
HUT65370A (en) * 1989-10-16 1994-05-02 Hem Res Inc Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
DE69102816T2 (de) * 1990-05-11 1995-03-16 Sankyo Co Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.

Also Published As

Publication number Publication date
EP0559297B1 (de) 1997-05-07
US4985437A (en) 1991-01-15
GR3017369T3 (en) 1995-12-31
ES2074981T3 (es) 1995-10-01
DE3752062T2 (de) 1997-09-11
EP0279990A2 (de) 1988-08-31
DE3751404T2 (de) 1995-12-21
DE3752062D1 (de) 1997-06-12
EP0279990B1 (de) 1995-07-12
EP0551963A2 (de) 1993-07-21
EP0279990A3 (en) 1990-11-28
ATE152623T1 (de) 1997-05-15
EP0559297A1 (de) 1993-09-08
DE3751404D1 (de) 1995-08-17
JPS63277623A (ja) 1988-11-15
JP2608079B2 (ja) 1997-05-07
EP0551963A3 (en) 1993-09-01

Similar Documents

Publication Publication Date Title
ATE124865T1 (de) Verwendung von heterocyclischen verbindungen zur behandlung von bewusstseinsstörungen.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
BR9206500A (pt) Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ATE182590T1 (de) Heterozyklische verbindungen für die behandlung von kardiovaskular- und zentralnervensystem störungen
DE3689099D1 (de) Verwendung von angiotensin-converting-enzym-inhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
BG103089A (en) Indoline derivatives useful as 5-ht-2c-receptor antagonists
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
DE69833557D1 (de) Verwendung von spezifischen 'steady-state' calcium-r-kanalblockern
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee